Early prostate cancer antigens (EPCA), polynucleotide sequences encoding them, and their use
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorRobert H. Getzenberg
Life of this patent
Estimating the term…
Abstract
A novel prostate cancer marker is described that is found in cancerous and normal prostate cells of individuals that have prostate cancer but is not found in the prostate of individuals without prostate cancer. The marker also is present in normal tissue adjacent to tumor tissue in individuals having prostate cancer. The marker, however, is absent in the prostate of individuals without prostate cancer. Methods employing the novel prostate cancer marker of the invention to predict the occurrence of the prostate disease, monitor the progression of prostate cancer and effect the treatment of prostate cancer, also are described.
Claims6
A method of diagnosing prostate cancer in a subject comprising (a) contacting a biological fluid sample or prostatic tissue specimen from the subject with an antibody which binds to SEQ ID NO:
- 1;(b) detecting binding of the antibody in the specimen;
- and (c) correlating the detected binding to prostate cancer.
A method of diagnosing prostatic intra-epithelial neoplasia (PIN) in a subject comprising (a) contacting a plasma or prostatic tissue specimen from the subject with an antibody which binds SEQ ID NO:
- 1, (b) detecting binding of the antibody in the specimen, and (c) correlating the detected binding to PIN.
Dependencies are inferred from the claim text.